Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib in Recurrent or Persistent Endometrial Carcinoma
NCT00888173Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Jul 2009
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brivanib in endometrial carcinoma, sponsored by GOG Foundation. Primary endpoints: Progression-free Survival > 6 Months and Objective Tumor Response up to 6 months. Started Jul 2009; status: completed.
02
Drugs
brivanib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT00888173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00888173.